Skip to content

Clinical study of Zhenzhu Qingyuan granule in the treatment of gastroesophageal reflux disease of liver-stomach heat retention type

Clinical study of Zhenzhu Qingyuan granule in the treatment of gastroesophageal reflux disease of liver-stomach heat retention type

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036656
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal reflex disease

Interventions

Sponsors

Xiyuan Hospital CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. The age ranged from 18 to 65 years old. 2. The patients who meet the GERD diagnostic criteria were divided into three types: NERD, RE and BE according to the results of gastroscopy. 3. Results of gastroscopy in Grade-A Tertiary Hospital within 2 weeks of approval. 4. All the patients were in accordance with the diagnosis of liver-stomach heat retention type. 5. Those who have not taken traditional Chinese medicine for the treatment of GERD for at least 3 months. 6. Volunteer to participate in this experiment and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe peptic ulcer, history of digestive tract surgery, gastrointestinal malignant disease and other serious complications. 2. Pregnant or lactating women. 3. Patients with severe liver and kidney dysfunction, malignant tumors, and cardiovascular and cerebrovascular diseases assessed by anesthesiologists who cannot tolerate general anesthesia. 4. Patients with other diseases such as immunity and organ failure. 5. Combined with mental patients who are unable to control the possibility of injuring others. 6. Patients with other serious infectious diseases, such as pulmonary tuberculosis and positive anti-HIV. 7. Those who have participated in other clinical trials in recent 3 months.

Design outcomes

Primary

MeasureTime frame
TCM symptom score;

Secondary

MeasureTime frame
Inflammation score under endoscopy;Reflux symptom score;RDQ;Gerd Q;

Countries

China

Contacts

Public ContactDang Zhongqin

Henan Province Hospital of TCM

dzhqn@126.com+86 13653717369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026